Qlif-11. classification of dermatologic adverse events and management strategies in patients receiving therapy with optune for high grade gliomas

OptuneTM is an FDA-approved novel delivery system which administers tumor treatment fields in the management of newly diagnosed and recurrent glioblastoma (GBM). Recommended usage is 18 hours per day, which may be limited by its only significant adverse event: medical site reaction or skin reaction. An attempt to describe these dermatologic adverse events (dAEs) was proposed by Lacouture et al in mid-2014. Unfortunately, this system was not readily adopted into clinical practice and was not included as part of the sentinel EF-14 trial. Skin reactions (dAEs) were reported as 16% for the EF-11 patients and 43% for the patients participating in EF-14. Additionally, the classification of dAEs are not adequately described via the CTCAE, which is the standard for describing adverse events. We have proposed an algorithm for the identification and management of dAEs which incorporates four categories: contact dermatitis (allergic and irritant), erosions, ulcerations, and folliculitis. Each category is unique in its management and impact on delivery of therapy. We implemented this algorithm in the management of patients treated with OptuneTM via clinical trial and/or prescription between April 2014 and present. In a population of 33 patients with high grade gliomas (HGGs), we identified dAEs in approximately 30% of patients treated with OptuneTM for a minimum of seven days. Of those patients, contact dermatitis was the most common dAE, representing 24% (n=8). This only led to tre...
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: QUALITY OF LIFE Source Type: research